Y. Shiose

发表

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression

M. Murakami, Hirokazu Ishikawa, K. Koyama, 2022, PloS one.

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

C. Paweletz, P. Jänne, J. Köhler, 2021, Cancer Research.

Abstract 5192: EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402

P. Janne, J. Köhler, Heidi M. Haikala, 2020 .

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

M. Murakami, K. Wakita, T. Agatsuma, 2019, Clinical Cancer Research.

Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer.

E. Oki, M. Morita, H. Baba, 2014, Cancer research.

Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423

H. Aburatani, Tomohiko Fukuda, F. McCormick, 2014, PloS one.

Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.

Keisuke Yoshida, Hiroyuki Naito, Takahiko Seki, 2013, Bioorganic & medicinal chemistry.

Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.

M. Hashida, F. Yamashita, H. Kuga, 2007, Biological & pharmaceutical bulletin.

Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer.

Y. Izumi, H. Kuga, T. Abiko, 2007, Oncology reports.

Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.

M. Hashida, F. Yamashita, H. Kuga, 2007, Journal of pharmaceutical and biomedical analysis.

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

F. Gao, W. Yung, E. Sulman, 2017, Oncotarget.

Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial

H. Iwata, K. Yonemori, Kenichi Inoue, 2019, Poster Discussion Abstracts.

Therapeutics , Targets , and Chemical Biology Small Molecule Agonists of PPAR-g Exert Therapeutic Effects in Esophageal Cancer

E. Oki, M. Morita, H. Baba, 2014 .

A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951

H. Kuga, E. Kumazawa, Y. Shiose, 2005, Cancer Chemotherapy and Pharmacology.